SoundHound Inc.’s Houndify Voice AI Powers In-Car Assistant in Honda’s Newest European Models
27.8.2020 11:00:00 EEST | Business Wire | Press release
SoundHound Inc. Ⓡ the leading innovator of voice-enabled AI and conversational intelligence technologies, today announced a milestone in its strategic partnership with Honda Motor Company with the integration of its Houndify voice AI platform into the new Honda e electric car and the top selling Honda Jazz in Europe. The Honda Personal Assistant—powered by Houndify—gives drivers an in-car conversational interface allowing them to control their environment, while accessing navigation, entertainment, and information hands-free. The personal assistant supports five major European languages.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200827005197/en/
New Honda e and Jazz Cars in Europe to Feature In-Car Voice Assistant (Photo: Business Wire)
Houndify voice AI includes patented Speech-to-MeaningⓇ and Deep Meaning Understanding™ technologies to deliver unprecedented speed and accuracy in voice recognition and responses. The platform’s ability to understand context, such as the user’s location or previous queries, eliminates the need to repeat information and allows more natural conversations.
Through the power of Houndify’s voice AI, drivers and passengers can ask Honda Personal Assistant even the most complex questions, such as: “OK Honda, show me restaurants within five kilometers, except French and Japanese ones, that have Wi-Fi, have at least three stars, and are open past 10 pm.” Houndify’s ability to remember context allows for useful follow-up questions, such as “Does it have parking?” The natural language interface can proactively prompt for the next step, like directions to the destination. Deep navigation integration allows drivers to further the experience by asking questions such as, “Are there any convenience stores along the way?”
“Honda e is the first fully electric vehicle to feature Houndify’s voice AI platform, and Jazz is one of Honda’s most popular cars in Europe , ” said Keyvan Mohajer, CEO and co-founder of SoundHound Inc. “We are proud of our partnership with Honda Motor Company and look forward to the growing use of the Honda Personal Assistant in Europe.”
SoundHound Inc. and Honda Motor Company first announced their partnership in October 2018 and premiered their collaboration at the 2019 Tokyo Motor show, where they demonstrated the Honda Personal Assistant to positive reviews.
The voice-enabled Honda Personal Assistant is available on Honda e and select Honda Jazz models in French, German, Spanish, Italian, and English languages.
To learn more about Honda Personal Assistant, powered by Houndify, visit SoundHound Inc.’s Speech-to-Meaning blog.
Developers interested in exploring Houndify’s independent voice AI platform can visit Houndify.com to learn more and register for a free account.
About SoundHound Inc.:
SoundHound Inc. turns sound into understanding and actionable meaning. We believe in enabling humans to interact with the things around them in the same way we interact with each other: by speaking naturally to mobile phones, cars, apps, TVs, smart speakers, and every other part of the emerging ‘connected’ world. Our consumer app, Hound, leverages our Speech-to-MeaningⓇ and Deep Meaning Understanding™ technologies to create a groundbreaking smartphone experience, and is the first product to build on the Houndify platform. Our SoundHound App applies our technology to music, enabling people to discover, explore, and share the music around them, and even find the name of that song stuck in their heads by singing or humming. Through the Houndify platform, we aim to bring voice-enabled AI to everyone and enable others to build on top of it. We call this Collective AI. Our Mission: Houndify everything.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200827005197/en/
Contact information
Michael Zagorsek
SoundHound Inc.
408-441-3270
mike@soundhound.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom